Hydroxychloroquine added to usual care for type 2 diabetes in pregnancy
Tests hydroxychloroquine tablets added to usual care in pregnant women with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Hydroxychloroquine in Type 2 Diabetes During Pregnancy
Key facts
- Where
- Cheras, MalaysiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 45 years old?
Source: NCT06319560, who can take part
Where in Malaysia
- Antenatal clinic, UKM Medical CentreCheras, MalaysiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National University of Malaysia
- Trial code
- NCT06319560
- Record updated
- 12 June 2025
- Original description
The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus.Read full original descriptionShow less
Hydroxychloroquine as an Adjunct Therapy in the Management of Type 2 Diabetes in Pregnancy: A Randomised Controlled Trial
The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus.
The main questions it aims to answer are:
* Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy? * Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment
Inclusion: Singleton; Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus.
Exclusion: women on steroid therapy; autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease; chronic kidney disease; fetal anomaly; diabetic retinopathy; known thalassaemia or thalassaemia carrier.